Fermented Garlic Lettuce Powder and Cognitive Function in Adults With Mild Cognitive Impairment

January 8, 2026 updated by: Yong-il Shin, Pusan National University Yangsan Hospital

The Effect of Fermented Garlic Lettuce Powder on Cognitive Function in Adults With Mild Cognitive Impairment: An Investigator-Initiated, Randomized, Assessor-Blinded, Parallel-Group, Controlled, Single-Center Study

"This study aims to investigate the cognitive and psychological changes in adults with mild cognitive impairment (K-MoCA scores between 16 and 23) following daily consumption of fermented garlic lettuce powder for 2 months

Study Overview

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gyeongsangnam-do
      • Yangsan, Gyeongsangnam-do, South Korea
        • Pusan National University Yangsan Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults aged 19 years or older with K-MoCA scores between 16 and 23.
  • Individuals with sufficient vision and hearing to participate in the study without difficulty.
  • Participants who are currently taking medications or receiving treatments that may affect cognition and are able to maintain the same dosage and regimen throughout the study period.
  • Individuals who voluntarily agree to participate in the study and provide written informed consent.

Exclusion Criteria:

  • Individuals who have undergone vascular-related surgery within the past 6 months or gastrointestinal surgery that may affect absorption of the study product (excluding simple appendectomy or hernia repair).
  • Individuals with a clinically significant history of hypersensitivity to medications or dietary supplements.
  • Individuals with a history of alcohol or drug abuse.
  • Individuals unable to communicate effectively.
  • Individuals who have participated in more than two dietary supplement studies or clinical trials within the current year, or within the past 6 months.
  • Individuals deemed unable to participate safely or effectively in the study by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fermented Garlic Lettuce Powder
Participants receive fermented garlic lettuce powder, administered orally as three tablets per day for 2 months (total of 180 tablets).
The Garlic Lettuce Fermented Powder tablets (intervention group) are taken 3 tablets daily for 2 months, totaling 180 tablets
Placebo Comparator: Placebo Tablet
Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets
Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
K-MoCA
Time Frame: Assessments are performed at baseline and at 2 months.
The Korean version of the Montreal Cognitive Assessment (K-MoCA) is a cognitive screening tool with scores ranging from 0 to 30, with higher scores indicating better cognitive function. The outcome measure is the change in K-MoCA score.
Assessments are performed at baseline and at 2 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SVLT
Time Frame: Assessments are performed at baseline and at 2 months.
The Seoul Verbal Learning Test (SVLT) is a neuropsychological assessment tool used to evaluate verbal memory performance. Scores range from 0 to 36, with higher scores indicating better memory function.
Assessments are performed at baseline and at 2 months.
KCWS
Time Frame: Assessments are performed at baseline and at 2 months.
The Korean Color-Word Stroop Test (KCWS) is a neuropsychological assessment used to evaluate executive function and cognitive control. Performance is measured by the number of correct responses within 1- and 2-minute intervals, with higher scores indicating better cognitive function.
Assessments are performed at baseline and at 2 months.
RCFT
Time Frame: Assessments are performed at baseline and at 2 months.
The Rey Complex Figure Test (RCFT) is a neuropsychological assessment used to evaluate visuospatial constructional ability and visual memory. Scores range from 0 to 36, with higher scores indicating better memory performance.
Assessments are performed at baseline and at 2 months.
DST
Time Frame: Assessments are performed at baseline and at 2 months.
The Digit Span Test (DST) is a neuropsychological assessment used to evaluate attention and working memory. Scores range from 0 to 24, with higher scores indicating better concentration and attention.
Assessments are performed at baseline and at 2 months.
COWAT
Time Frame: Assessments are performed at baseline and at 2 months.
The Controlled Oral Word Association Test (COWAT) is a neuropsychological assessment used to evaluate verbal fluency and executive function. Scores range from 0 to 27, with higher scores indicating better verbal fluency, executive function, attention, and problem-solving abilities.
Assessments are performed at baseline and at 2 months.
BDI
Time Frame: Assessments are performed at baseline and at 2 months.
The Beck Depression Inventory (BDI) is a self-report questionnaire used to assess the severity of depressive symptoms. Each item is scored from 0 to 3, with total scores ranging from 0 to 63, where higher scores indicate more severe depressive symptoms.
Assessments are performed at baseline and at 2 months.
EQ-5D
Time Frame: Assessments are performed at baseline and at 2 months.
The EuroQol-5 Dimension (EQ-5D) is a standardized instrument for measuring health-related quality of life. Scores range from 0 to 100, with lower scores indicating better perceived health status and higher scores reflecting more severe health problems.
Assessments are performed at baseline and at 2 months.
MFS
Time Frame: Assessments are performed at baseline and at 2 months.
The Multidimensional Fatigue Scale (MFS) is a self-report questionnaire used to assess fatigue across multiple dimensions. Each dimension is rated from 0 to 20, with a total score ranging from 0 to 100. Lower scores indicate less fatigue, while higher scores reflect more severe fatigue.
Assessments are performed at baseline and at 2 months.
PWI-SF
Time Frame: Assessments are performed at baseline and at 2 months.
The Psychological Well-Being Index-Short Form (PWI-SF) is a self-report questionnaire used to assess psychological well-being. Each dimension is rated from 0 to 20, with total scores ranging from 0 to 54, where higher scores indicate better psychological well-being, life satisfaction, and emotional stability.
Assessments are performed at baseline and at 2 months.
LSEQ
Time Frame: Assessments are performed at baseline and at 2 months.
The Leeds Sleep Evaluation Questionnaire (LSEQ) is a self-report instrument used to assess subjective sleep quality. Scores are based on a scale from 0 to 100, with higher scores indicating better sleep quality and lower scores reflecting greater sleep disturbance.
Assessments are performed at baseline and at 2 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 19, 2025

Primary Completion (Estimated)

January 21, 2026

Study Completion (Estimated)

January 21, 2026

Study Registration Dates

First Submitted

December 23, 2025

First Submitted That Met QC Criteria

December 23, 2025

First Posted (Estimated)

January 7, 2026

Study Record Updates

Last Update Posted (Estimated)

January 12, 2026

Last Update Submitted That Met QC Criteria

January 8, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment (MCI)

Clinical Trials on Garlic Lettuce Fermented Powder

Subscribe